| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Scottish Pulmonary Vascular Unit, Western Infirmary, Glasgow, UK. 2 Dept of Cardiology, Erasme University Hospital, Brussels, Belgium. 3 Institute of Cardiology, University of Bologna, Bologna, Italy. 4 University of Colorado Medical Center, Denver, USA
CORRESPONDENCE: A. Peacock, Scottish Pulmonary Vascular Unit, Western Infirmary, Glasgow, UK. Fax: 44 1412116334, E-mail: apeacock@udcf.gla.ac.uk
Keywords: Biological markers, exercise physiology, haemodynamics, imaging, pulmonary hypertension, quality of life
Received: October 30, 2003
Accepted December 10, 2003
Abstract
Pulmonary arterial hypertension is a rare disease of poor prognosis.
Despite its rarity >1,000 patients have been randomised in placebo-controlled trials using novel therapies, including prostacyclin analogues, endothelin receptor antagonists and, most recently, phosphodiesterase 5 inhibitors. Nearly all of these trials have used exercise capacity, measured by the unencouraged 6-min walking distance, as the primary end point and a variety of other measurements as secondary end points. This approach has been productive, leading to the licensing of a number of effective treatments. Future clinical trials, however, will probably assess drug combinations, make comparisons between drugs and include less severely ill patients. It is, therefore, timely to examine the end points used.
The authors discussed the various end points that have been used in the past and possible end points that might be used in the future. End points considered included measurements of: exercise capacity, haemodynamics, quality of life, imaging of the right heart and circulation, and chemical markers of pulmonary hypertension.
Many of these show promise but will have to be used in parallel and compared with conventional end points such as the 6-min walking distance before their value can be demonstrated convincingly to the regulatory authorities.
This article has been cited by other articles:
|
|
 |
|
  S. Provencher, P. Herve, O. Sitbon, M. Humbert, G. Simonneau, and D. Chemla Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension Eur. Respir. J., August 1, 2008; 32(2): 393 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Ventetuolo, R. L. Benza, A. J. Peacock, R. T. Zamanian, D. B. Badesch, and S. M. Kawut Surrogate and Combined End Points in Pulmonary Arterial Hypertension Proceedings of the ATS, July 15, 2008; 5(5): 617 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Helman Jr, A. W. Brown, J. L. Jackson, and A. F. Shorr Analyzing the Short-term Effect of Placebo Therapy in Pulmonary Arterial Hypertension: Potential Implications for the Design of Future Clinical Trials Chest, September 1, 2007; 132(3): 764 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S C Apostolopoulou, A Manginas, D V Cokkinos, and S Rammos Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study Heart, March 1, 2007; 93(3): 350 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gomberg-Maitland Learning to pair therapies and the expanding matrix for pulmonary arterial hypertension: is more better? Eur. Respir. J., October 1, 2006; 28(4): 683 - 686. [Full Text] [PDF]
|
|
|
|
|
|
A. Peacock, G. Simonneau, and L. Rubin Controversies, Uncertainties and Future Research on the Treatment of Chronic Thromboembolic Pulmonary Hypertension Proceedings of the ATS, September 1, 2006; 3(7): 608 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Provencher, D. Chemla, P. Herve, O. Sitbon, M. Humbert, and G. Simonneau Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension Eur. Respir. J., January 1, 2006; 27(1): 114 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-C. Ong, A. Earnest, and S.-J. Lu A Multidimensional Grading System (BODE Index) as Predictor of Hospitalization for COPD Chest, December 1, 2005; 128(6): 3810 - 3816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Kawut, E. M. Horn, K. K. Berekashvili, A. C. Widlitz, E. B. Rosenzweig, and R. J. Barst von Willebrand Factor Independently Predicts Long-term Survival in Patients With Pulmonary Arterial Hypertension Chest, October 1, 2005; 128(4): 2355 - 2362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vonk-Noordegraaf, S. A. van Wolferen, J. T. Marcus, A. Boonstra, P. E. Postmus, J. W. L. Peeters, and A. J. Peacock Noninvasive assessment and monitoring of the pulmonary circulation Eur. Respir. J., April 1, 2005; 25(4): 758 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278. [Full Text] [PDF]
|
|
|
|
|
|
M. Sofia, M. Maniscalco, P. Carratu, and O. Resta End points for pulmonary arterial hypertension: a way backward Eur. Respir. J., November 1, 2004; 24(5): 890 - 891. [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. A. Calverley The GOLD Classification Has Advanced Understanding of COPD Am. J. Respir. Crit. Care Med., August 1, 2004; 170(3): 211 - 212. [Full Text] [PDF]
|
|
|
|
|
|
S.M. Kawut and H.I. Palevsky New answers raise new questions in pulmonary arterial hypertension Eur. Respir. J., June 1, 2004; 23(6): 799 - 801. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
